ASPEN-03: A randomized phase II study of evorpacept in combination with pembrolizumab in patients with recurrent, unresectable or metastatic (R/M) PD-L1 positive head and neck squamous cell carcinoma (HNSCC)

Category Primary study
ConferenceEuropean Society For Medical Oncology Congress, ESMO 2025
Year 2025
This article has no abstract
Epistemonikos ID: b58997a1343fb3f49b653e536f087f0a85a95e65
First added on: May 16, 2026